Avalon Trust’s Nurix Therapeutics NRIX Stock Holding History

Avalon Trust’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.1K	Hold	2,650	–	–	﹤0.01%	305
2025 Q4	$50.3K	Hold	2,650	–	–	﹤0.01%	279
2025 Q3	$24.5K	Hold	2,650	–	–	﹤0.01%	381
2025 Q2	$30.2K	Hold	2,650	–	–	﹤0.01%	298
2025 Q1	$31.5K	Hold	2,650	–	–	﹤0.01%	305
2024 Q4	$49.9K	Sell	2,650 -1,500	-36%	-$34.4K	﹤0.01%	228
2024 Q3	$93.3K	Sell	4,150 -2,906	-41%	-$65.8K	0.01%	172
2024 Q2	$147K	Hold	7,056	–	–	0.01%	143
2024 Q1	$104K	Hold	7,056	–	–	0.01%	172
2023 Q4	$72.8K	Hold	7,056	–	–	0.01%	181
2023 Q3	$55.5K	Hold	7,056	–	–	0.01%	183
2023 Q2	$70.5K	Hold	7,056	–	–	0.01%	183
2023 Q1	$62.7K	Buy	+7,056	New	+$73.5K	0.01%	186

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Avalon Trust's NRIX Position: Q1 2026 in Review

Avalon Trust held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 2,650 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #305.

Avalon Trust first reported a position in NRIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $147K in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Avalon Trust held 2,650 shares of Nurix Therapeutics worth $41.1K as of Q1 2026.
Avalon Trust left its Nurix Therapeutics share count unchanged in Q1 2026.
Nurix Therapeutics made up ﹤0.01% of Avalon Trust's portfolio in Q1 2026, its #305 holding.
Avalon Trust first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 13 quarters since.
Avalon Trust's Nurix Therapeutics position peaked at $147K in Q2 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Avalon Trust's 13F filing for Q1 2026, filed 6 May 2026.